Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
12.04
-0.49 (-3.91%)
Jul 13, 2026, 10:01 AM EDT - Market open
TNXP Revenue
Tonix Pharmaceuticals Holding had revenue of $6.88M in the quarter ending March 31, 2026, with 183.16% growth. This brings the company's revenue in the last twelve months to $17.56M, up 74.84% year-over-year. In the year 2025, Tonix Pharmaceuticals Holding had annual revenue of $13.11M with 29.85% growth.
Revenue (ttm)
$17.56M
Revenue Growth
+74.84%
P/S Ratio
11.38
Revenue / Employee
$123,634
Employees
142
Market Cap
191.93M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.11M | 3.01M | 29.85% |
| Dec 31, 2024 | 10.09M | 2.33M | 29.94% |
| Dec 31, 2023 | 7.77M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 76.38M |
| Arcturus Therapeutics Holdings | 54.71M |
| Q32 Bio | 53.74M |
| Voyager Therapeutics | 36.49M |
| Caribou Biosciences | 11.20M |
| Korro Bio | 3.84M |
| Outlook Therapeutics | 333.14K |
TNXP News
- 2 hours ago - Tonix Pharmaceuticals announces managed Medicare agreement for Tonmya - TheFly
- 3 hours ago - Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA® - GlobeNewsWire
- 12 days ago - Tonix Pharmaceuticals Holding Slides: Investor presentation - Filings
- 14 days ago - Tonix Pharmaceuticals enrolls first patient in HORIZON study - TheFly
- 14 days ago - Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) - GlobeNewsWire
- 18 days ago - Tonix Pharmaceuticals initiated with a Strong Buy at Raymond James - TheFly
- 4 weeks ago - Tonix Pharmaceuticals Holding Slides: Investor presentation - Filings
- 4 weeks ago - Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026 - GlobeNewsWire